PATENT CLAIM ANALYSIS

Application Number: 15770763
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "210160"]

Abstract:
The present invention relates to compounds of general formula (I), wherein D 1  to D 3 , -A-, n, R 1 , R 2 , Y 1 , L and  y2  are defined as in claim  1 , which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.

Claim (Index 2):
A compound according to  claim 1 , wherein\n R 1  and R 2  together with the carbon atom they are attached to form a 3-5 membered saturated ring system, or a salt thereof.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.57143
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15770762', '15953523', '15946837', '15508122', '15747818']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7698899779286323
- 35 USC 102 Novelty (BERT): 0.5652006588867926
- Combined Prediction Score: 0.7494210460244485
- Mean Citation Score: 333.686524
- Max Citation Score: 456.89117000000016
- Similarity Product: 314.7449441258318

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test